Completed PHASE4 INTERVENTIONAL NCT00239629

Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial

Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis

Sponsor: Eli Lilly and Company

Conditions Postmenopausal Osteoporosis

Interventions Strontium ranelate Teriparatide Transiliac bone biopsy

Updated 6 times since 2017 Last updated: Jun 11, 2007 Started: Sep 30, 2005 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Postmenopausal Osteoporosis, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Guadalajara, Mexico , Haifa, Israel , Hamburg, Germany , Heidelberg, Germany , Kifissia, Greece , Madrid, Spain , Magdeburg, Germany , Prague, Czechia , Thessaloniki, Greece and 1 more location